Michelle C Janelsins1, Charles E Heckler1, Luke J Peppone1, Tim A Ahles1, Supriya G Mohile1, Karen M Mustian1, Oxana Palesh1, Ann M O'Mara1, Lori M Minasian1, Annalynn M Williams1, Allison Magnuson1, Jodi Geer1, Shaker R Dakhil1, Judith O Hopkins1, Gary R Morrow1. 1. Michelle C. Janelsins, Charles E. Heckler, Luke J. Peppone, Supriya G. Mohile, Karen M. Mustian, Annalynn M. Williams, Allison Magnuson, and Gary R. Morrow, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester; Tim A. Ahles, Memorial Sloan Kettering Cancer Center, New York, NY; Oxana Palesh, Stanford Cancer Center, Stanford, CA; Ann M. O'Mara and Lori M. Minasian, National Cancer Institute (NCI), National Institutes of Health, Rockville, MD; Jodi Geer, Metro Minnesota NCI Community Oncology Research Program (NCORP), Saint Louis Park, MN; Shaker R. Dakhil, Wichita NCORP, Wichita, KS; and Judith O. Hopkins, Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, NC.
Abstract
PURPOSE: Cancer-related cognitive impairment (CRCI) is an important clinical problem in patients with breast cancer receiving chemotherapy. Nationwide longitudinal studies are needed to understand the trajectory and severity of CRCI in specific cognitive domains. PATIENTS AND METHODS: The overall objective of this nationwide, prospective, observational study conducted within the National Cancer Institute Community Clinical Oncology Research Program was to assess trajectories in specific cognitive domains in patients with breast cancer (stage I-IIIC) receiving chemotherapy, from pre- (A1) to postchemotherapy (A2) and from prechemotherapy to 6 months postchemotherapy (A3); controls were assessed at the same time-equivalent points. The primary aim assessed visual memory using the Cambridge Neuropsychological Test Automated Battery Delayed Match to Sample test by longitudinal mixed models including A1, A2, and A3 and adjusting for age, education, race, cognitive reserve score, and baseline anxiety and depressive symptoms. We also assessed trajectories of CRCI in other aspects of memory as well as in attention and executive function with computerized, paper-based, and telephone-based cognitive tests. RESULTS: In total, 580 patients with breast cancer (mean age, 53.4 years) and 363 controls (mean age, 52.6 years) were assessed. On the Delayed Match to Sample test, the longitudinal mixed model results revealed a significant group-by-time effect ( P < .005); patients declined over time from prechemotherapy (A1) to 6 months postchemotherapy (A3; P = .005), but controls did not change ( P = .426). The group difference between patients and controls was also significant, revealing declines in patients but not controls ( P = .017). Several other models of computerized, standard, and telephone tests indicated significantly worse performance by patients compared with controls from pre- to postchemotherapy and from prechemotherapy to 6 months postchemotherapy. CONCLUSION: This nationwide study showed CRCI in patients with breast cancer affects multiple cognitive domains for at least 6 months postchemotherapy.
PURPOSE:Cancer-related cognitive impairment (CRCI) is an important clinical problem in patients with breast cancer receiving chemotherapy. Nationwide longitudinal studies are needed to understand the trajectory and severity of CRCI in specific cognitive domains. PATIENTS AND METHODS: The overall objective of this nationwide, prospective, observational study conducted within the National Cancer Institute Community Clinical Oncology Research Program was to assess trajectories in specific cognitive domains in patients with breast cancer (stage I-IIIC) receiving chemotherapy, from pre- (A1) to postchemotherapy (A2) and from prechemotherapy to 6 months postchemotherapy (A3); controls were assessed at the same time-equivalent points. The primary aim assessed visual memory using the Cambridge Neuropsychological Test Automated Battery Delayed Match to Sample test by longitudinal mixed models including A1, A2, and A3 and adjusting for age, education, race, cognitive reserve score, and baseline anxiety and depressive symptoms. We also assessed trajectories of CRCI in other aspects of memory as well as in attention and executive function with computerized, paper-based, and telephone-based cognitive tests. RESULTS: In total, 580 patients with breast cancer (mean age, 53.4 years) and 363 controls (mean age, 52.6 years) were assessed. On the Delayed Match to Sample test, the longitudinal mixed model results revealed a significant group-by-time effect ( P < .005); patients declined over time from prechemotherapy (A1) to 6 months postchemotherapy (A3; P = .005), but controls did not change ( P = .426). The group difference between patients and controls was also significant, revealing declines in patients but not controls ( P = .017). Several other models of computerized, standard, and telephone tests indicated significantly worse performance by patients compared with controls from pre- to postchemotherapy and from prechemotherapy to 6 months postchemotherapy. CONCLUSION: This nationwide study showed CRCI in patients with breast cancer affects multiple cognitive domains for at least 6 months postchemotherapy.
Authors: S Russo; M M A Nielen; J C Boon; I P Kema; P H B Willemse; E G E de Vries; J Korf; J A den Boer Journal: Psychopharmacology (Berl) Date: 2003-04-15 Impact factor: 4.530
Authors: Janette L Vardy; Haryana M Dhillon; Gregory R Pond; Sean B Rourke; Tsegaye Bekele; Corrinne Renton; Anna Dodd; Haibo Zhang; Philip Beale; Stephen Clarke; Ian F Tannock Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544
Authors: Michelle C Janelsins; Charles E Heckler; Bryan D Thompson; Robert A Gross; Lisa A Opanashuk; Deborah A Cory-Slechta Journal: Neurotoxicology Date: 2016-06-28 Impact factor: 4.294
Authors: James C Root; Elizabeth Ryan; Gregory Barnett; Charissa Andreotti; Kemi Bolutayo; Tim Ahles Journal: Psychooncology Date: 2014-07-05 Impact factor: 3.894
Authors: V Jenkins; V Shilling; G Deutsch; D Bloomfield; R Morris; S Allan; H Bishop; N Hodson; S Mitra; G Sadler; E Shah; R Stein; S Whitehead; J Winstanley Journal: Br J Cancer Date: 2006-03-27 Impact factor: 7.640
Authors: Lynne I Wagner; Robert J Gray; Joseph A Sparano; Timothy J Whelan; Sofia F Garcia; Betina Yanez; Amye J Tevaarwerk; Ruth C Carlos; Kathy S Albain; John A Olson; Matthew P Goetz; Kathleen I Pritchard; Daniel F Hayes; Charles E Geyer; E Claire Dees; Worta J McCaskill-Stevens; Lori M Minasian; George W Sledge; David Cella Journal: J Clin Oncol Date: 2020-04-09 Impact factor: 44.544
Authors: José Alberto Domínguez-Alonso; David Conde-Estévez; David Bosch; Maria Pi-Figueras; Ignacio Tusquets Journal: Clin Transl Oncol Date: 2020-05-24 Impact factor: 3.405
Authors: Allison Magnuson; Lianlian Lei; Nikesha Gilmore; Amber S Kleckner; Feng V Lin; Robert Ferguson; Arti Hurria; Marsha N Wittink; Benjamin T Esparaz; Jeffrey K Giguere; Jamal Misleh; Javier Bautista; Supriya G Mohile; Michelle C Janelsins Journal: J Am Geriatr Soc Date: 2019-05 Impact factor: 5.562
Authors: Carmen Kohler; Ming Chang; Yu-Yin Allemann-Su; Marcus Vetter; Miyeon Jung; Misook Jung; Yvette Conley; Steven Paul; Kord M Kober; Bruce A Cooper; Betty Smoot; Jon D Levine; Christine Miaskowski; Maria C Katapodi Journal: J Pain Symptom Manage Date: 2020-01-15 Impact factor: 3.612
Authors: Danielle B Tometich; Brent J Small; Judith E Carroll; Wanting Zhai; George Luta; Xingtao Zhou; Lindsay C Kobayashi; Tim Ahles; Andrew J Saykin; Jonathan D Clapp; Heather S L Jim; Paul B Jacobsen; Arti Hurria; Deena Graham; Brenna C McDonald; Neelima Denduluri; Martine Extermann; Claudine Isaacs; Asma Dilawari; James Root; Christine Rini; Jeanne S Mandelblatt Journal: J Pain Symptom Manage Date: 2018-11-23 Impact factor: 3.612
Authors: AnnaLynn M Williams; Carly Paterson Khan; Charles E Heckler; Debra L Barton; Mary Ontko; Jodi Geer; Amber S Kleckner; Shaker Dakhil; Jerry Mitchell; Karen M Mustian; Luke J Peppone; Victor Kipnis; Charles S Kamen; Ann M O'Mara; Michelle C Janelsins Journal: Breast Cancer Res Treat Date: 2021-01-04 Impact factor: 4.872
Authors: AnnaLynn M Williams; Edwin van Wijngaarden; Christopher L Seplaki; Charles E Heckler; Miriam T Weber; Paul M Barr; Clive S Zent; Michelle C Janelsins Journal: Leuk Lymphoma Date: 2020-03-09